findmyKOL
Clinical trialNCT05797168RecruitingPhase 1/PHASE2Interventional

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

SponsorAstraZenecaEnrollment506Endometrial CancerLung AdenocarcinomaLung Squamous Cell CarcinomaOvarian Cancer
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

60 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia
  • Research Site

    Liverpool, Australia

    Recruiting
  • Research Site

    Melbourne, Australia

    Recruiting
Canada
  • Research Site

    Edmonton, Alberta, Canada

    Recruiting
  • Research Site

    London, Ontario, Canada

    Recruiting
  • Research Site

    Toronto, Ontario, Canada

    Recruiting
  • Research Site

    Montreal, Quebec, Canada

    Recruiting
  • Research Site

    Montreal, Quebec, Canada

    Recruiting
China
  • Research Site

    Chengdu, China

    Recruiting
  • Research Site

    Chongqing, China

    Recruiting
  • Research Site

    Guangzhou, China

    Recruiting
  • Research Site

    Guangzhou, China

    Recruiting
  • Research Site

    Jinan, China

    Recruiting
  • Research Site

    Xi'an, China

    Recruiting
  • Research Site

    Zhengzhou, China

    Recruiting
Germany
  • Research Site

    Berlin, Germany

    Recruiting
  • Research Site

    Essen, Germany

    Not, yet, recruiting
  • Research Site

    Freiburg im Breisgau, Germany

    Not, yet, recruiting
  • Research Site

    Hanover, Germany

    Recruiting
  • Research Site

    Leipzig, Germany

    Recruiting
  • Research Site

    Mannheim, Germany

    Recruiting
  • Research Site

    Regensburg, Germany

    Recruiting
Israel
  • Research Site

    Haifa, Israel

    Recruiting
  • Research Site

    Ramat Gan, Israel

    Recruiting
Japan
  • Research Site

    Hidaka-shi, Japan

    Recruiting
  • Research Site

    Kashiwa, Japan

    Recruiting
  • Research Site

    Kōtoku, Japan

    Recruiting
  • Research Site

    Sunto-gun, Japan

    Recruiting
  • Research Site

    Tokyo, Japan

    Recruiting
South Korea
  • Research Site

    Seoul, South Korea

    Recruiting
  • Research Site

    Seoul, South Korea

    Recruiting
Spain
  • Research Site

    Barcelona, Spain

    Recruiting
  • Research Site

    Madrid, Spain

    Recruiting
  • Research Site

    Madrid, Spain

    Recruiting
  • Research Site

    Málaga, Spain

    Recruiting
Taiwan
  • Research Site

    Taichung, Taiwan

    Recruiting
  • Research Site

    Tainan, Taiwan

    Recruiting
  • Research Site

    Taipei, Taiwan

    Recruiting
  • Research Site

    Taipei, Taiwan

    Recruiting
Turkey (Türkiye)
  • Research Site

    Ankara, Turkey (Türkiye)

    Recruiting
  • Research Site

    Ankara, Turkey (Türkiye)

    Recruiting
20 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

BevacizumabCarboplatinAzd9574PembrolizumabSaruparibTorvutatug samrotecan
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
5 Jun 2023
Primary completion
6 Jan 2028
Completion
6 Jan 2028
Last update posted
3 Jun 2026
Registered enrollment
506
Registry id
NCT05797168

Cross-registrations

EU-CTR / CTIS (EudraCT)2022-502576-23-00

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.